Centessa leverages a differentiated orexin agonist platform with multiple programs targeting significant unmet medical needs in sleep disorders, neurodegeneration, and neuropsychiatric conditions. The company also maintains an immuno-oncology program via its LockBody technology platform, providing pipeline diversification beyond its core orexin focus.
Cyborg Score Rationale
Centessa demonstrates strong clinical momentum with Phase 2a advancement of its lead ORX750 program and supportive preclinical data across multiple indications. Analyst consensus remains constructive with strong buy ratings, though as a clinical-stage biotech, execution risk remains material.
Top Insights
Lead program ORX750 advancing in Phase 2a for narcolepsy and idiopathic hypersomnia with positive animal model data showing antidepressive effects
Broader orexin platform addresses large neurological/neuropsychiatric markets with multiple shots on goal including ORX142 and ORX489
CEO transition in early 2026 with Mario Alberto Accardi, founder of Orexin Program, now leading company through critical clinical milestones
Stock trading at significant discount to analyst fair value estimates with average 12-month target suggesting 47%+ upside potential
Named Competitors
Wakix (pitolisant) — Histamine H3-receptor antagonist for narcolepsy
Xywav — Sodium oxybate for narcolepsy and IH
Sunosi (solriamfetol) — Dopamine/norepinephrine reuptake inhibitor for EDS
Recent Developments
(Feb 2026) ORX489 Phase 1 trial early safety readout anticipated
(Feb 2026) New CEO transition completed with program founder appointed to lead company
(Jan 2026) Achieved early development milestones with Japanese partner Nxera Pharma on ORX142
(Feb 2026) Positive preclinical data for ORX750 showing antidepressive effects in depression model
Open the full interactive Centessa Pharmaceuticals plc report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.